REG - Eden Research plc - Completion of Conditional Placing

Eden ResearchAnnouncement

05/10/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231005:nRSE7388Oa&default-theme=true

RNS Number : 7388O  Eden Research plc  05 October 2023

5 October 2023

 

 

Eden Research plc

("Eden", the "Group" or the "Company")

 

Completion of Conditional Placing

 

Eden Research plc (AIM: EDEN), the AIM-quoted company that develops and
supplies breakthrough biopesticide products and natural microencapsulation
technologies to the global crop protection, animal health and consumer
products industries, provides an update on the proposed completion of its
Conditional Placing, as originally announced on 28 July 2023.

 

Eden is pleased to announce that 129,230,769 Ordinary Shares will be issued
via the Conditional Placing, raising £8.4 million (before expenses). This
includes subscriptions for 7,692,307 Ordinary Shares more than the minimum
announced at the time of the initial announcement, raising a further £0.5
million.  Consequently, a total of £9.9 million (before expenses) has been
raised pursuant to the Firm Capital Raising, the Retail Offer and the
Conditional Placing.

 

Application has been made for 129,230,769 Conditional Placing Shares to be
admitted to trading on AIM ("Admission"). Admission is expected to take place
at 8.00 a.m. on 6 October 2023.

 

Following the Admission, the total number of Ordinary Shares in the capital of
the Company in issue will be 533,352,523 with each Ordinary Share carrying the
right to one vote. There are no Ordinary Shares held in treasury and therefore
the total number of voting rights in the company is expected to be
533,352,523. The above figure may be used by Shareholders in the Company as
the denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
share capital of the Company under the FCA's Disclosure, Guidance and
Transparency Rules.

 

Capitalised terms used in this announcement have the meaning given to them in
the placing and retail offer announcement dated 28 July 2023, unless otherwise
defined in this announcement.

 

 

For further information, please contact:

 Eden Research plc                                            www.edenresearch.com (http://www.edenresearch.com)

 Sean Smith / Alex Abrey

 Cavendish Securities Plc (Nominated advisor and broker)
 Giles Balleny (Corporate Finance) / Michael Johnson (Sales)  020 7397 8900

 Hawthorn Advisors (Financial PR)
 Simon Woods                                                  eden@hawthornadvisors.com (mailto:eden@hawthornadvisors.com)

Felix Meston

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEMIBPTMTMMBFJ